- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Diplomat becomes distributor of recently approved cancer drug
- FDA advisory panel to consider OTC status of NSAIDs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Reports: ESI may start 'price war' over new hepatitis C drugs
SCHAUMBURG, Ill. — Sagent has received approval from the Food and Drug Administration for its antibacterial drug.
The drug maker said that the FDA approved polymyxin B for injection USP. Sagent said that polymyxin B sulfate is used to treat infections of the urinary tract, meninges and bloodstream caused by susceptible strains of Pseudomonas aeruginosa.
The drug was developed in partnership with Strides Arcolab. Under the collaboration, Strides develops and supplies injectable products that Sagent will market in the United States.